• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

    2/1/23 4:43:08 PM ET
    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $SMFR alert in real time by email
    SC 13D/A 1 form_sc13da-genedx.htm

     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*
     
    GeneDx Holdings Corp.
    (Name of Issuer)
     
    CMLS Holdings LLC
    Eli Casdin and Keith Meister
    c/o Corvex Management LP
    667 Madison Avenue
    New York, New York 10065
    (212) 474-6745
    (Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications)
     
    Class A common stock, $0.0001 par value per share
    (Title of Class of Securities)
     
    81663L101
    (CUSIP Number)
     
    January 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    CUSIP No. 81663L101


    1
     
    NAME OF REPORTING PERSONS
     
    CMLS HOLDINGS LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    17,730,419 (1)(2)(3)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    17,730,419 (1)(2)(3)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    17,730,419 (1)(2)(3)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
     
    ☐
    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    2.2% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    HC, OO
     
      


    CUSIP No. 81663L101


    1
     
    NAME OF REPORTING PERSONS
     
    C-LSH LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    17,730,419 (1)(2)(3)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    17,730,419 (1)(2)(3)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    17,730,419 (1)(2)(3)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
     
    ☐
    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    2.2% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    HC, OO




    CUSIP No. 81663L101


    1
     
    NAME OF REPORTING PERSONS
     
    M-LSH LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    17,730,419 (1)(2)(3)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    17,730,419 (1)(2)(3)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    17,730,419 (1)(2)(3)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
     
    ☐
    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    2.2% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    HC, OO



    CUSIP No. 81663L101


    1
     
    NAME OF REPORTING PERSONS
     
    ELI CASDIN
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    35,122 (7)
     
    8
     
    SHARED VOTING POWER
     
    119,882,204 (1)(2)(3)(5)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    35,122 (7)
     
    10
     
    SHARED DISPOSITIVE POWER
     
    119,882,204 (1)(2)(3)(5)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    119,882,204 (1)(2)(3)(5)(7)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐
     
    119,917,326
    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    15.1% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    HC, IN



    CUSIP No. 81663L101

    1
     
    NAME OF REPORTING PERSONS
     
    CASDIN CAPITAL, LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    102,151,785 (5)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    102,151,785 (5)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    102,151,785 (5)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐
     

    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    13.0% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    IA, OO


     
    CUSIP No. 81663L101

    1
     
    NAME OF REPORTING PERSONS
     
    CASDIN PARTNERS GP, LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    102,151,785(5)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    102,151,785(5)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    102,151,785(5)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐
     

    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    13.0% (4)(5)
    14
     
    TYPE OF REPORTING PERSON*
     
    OO



    CUSIP No. 81663L101

    1
     
    NAME OF REPORTING PERSONS
     
    CASDIN PARTNERS MASTER FUND, L.P.
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    WC
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    87,866,042
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    87,866,042
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    87,866,042
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐ (3)
     

    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    11.2% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    PN



    CUSIP No. 81663L101

    1
     
    NAME OF REPORTING PERSONS
     
    CASDIN PARTNERS FO1-MSV, LP
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    WC
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    0
     
    8
     
    SHARED VOTING POWER
     
    14,285,743
     
    9
     
    SOLE DISPOSITIVE POWER
     
    0
     
    10
     
    SHARED DISPOSITIVE POWER
     
    14,285,743
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    14,285,743
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐
     

    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    1.8% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    PN


    CUSIP No. 81663L101

    1
     
    NAME OF REPORTING PERSONS
     
    KEITH A. MEISTER
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    OO
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    86,811,516 (6)
     
    8
     
    SHARED VOTING POWER
     
    17,730,419 (1)(2)(3)
     
    9
     
    SOLE DISPOSITIVE POWER
     
    86,811,516 (6)
     
    10
     
    SHARED DISPOSITIVE POWER
     
    17,730,419 (1)(2)(3)
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    104,541,935 (1)(2)(3)(6)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐
     

    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    13.2% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    HC, IN





    CUSIP No. 81663L101

    1
     
    NAME OF REPORTING PERSONS
     
    CORVEX MANAGEMENT LP
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    SOURCE OF FUNDS*
     
    AF
    5
     
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
     
    ☐
    6
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
     
    7
     
    SOLE VOTING POWER
     
    86,811,516 (6)
     
    8
     
    SHARED VOTING POWER
     
    0
     
    9
     
    SOLE DISPOSITIVE POWER
     
    86,811,516 (6)
     
    10
     
    SHARED DISPOSITIVE POWER
     
    0
     
     
     
     
     
     
     
    11
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    86,811,516 (6)
    12
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES☐
     

    13
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    11.0% (4)
    14
     
    TYPE OF REPORTING PERSON*
     
    PN, IA

     
    (1)
    Includes 10,993,750 shares of Class A common stock of GeneDx Holdings Corp. (the “Issuer”), par value $0.0001 per share (“Common Stock”).
    (2)
    Includes 6,736,669 shares of Common Stock issuable upon the exercise of 6,736,669 private placement warrants of the Issuer. On September 3, 2021, each private placement warrant became exercisable to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment, as described in the definitive proxy statement of the Issuer (File No. 001-39482) filed with the U.S. Securities Exchange Commission (the “SEC”) on July 2, 2021.





    (3)
    CMLS Holdings LLC is the record holder of the shares reported herein. The Board of Managers of CMLS Holdings LLC is comprised of Mr. Casdin and Mr. Meister who share voting and investment discretion with respect to the common stock held of record by CMLS Holdings LLC. C-LSH LLC and M-LSH LLC are the members of CMLS Holdings LLC, and Mr. Casdin and Mr. Meister are the managing members of C-LSH LLC and M-LSH LLC, respectively. As such, each of the foregoing may be deemed to have or share beneficial ownership of the Common Stock held directly by CMLS Holdings LLC.
    (4)
    Based on 810,000,334 shares of Common Stock outstanding as reported in the Issuer’s final prospectus on Form 424 filed with the SEC on January 30, 2023 following the offering reduced by the 22,364,624 Additional Direct Offering Shares (as defined below) plus 185,000 shares that the Issuer has informed the Reporting Persons that were issued as a partial exercise of the overallotment option and, for Reporting Persons that beneficially own warrants or options as reported in notes (2) and (7), plus warrants and options that would result in the issuance of new shares and exercisable within the next 60 days.
    (5)
    Casdin Partners Master Fund, LP is the holder of 87,866,042 shares reported herein. Casdin Partners FO1-MSV LP is the holder of 14,285,743 shares reported herein. Casdin Capital, LLC is the investment adviser to Casdin Partners Master Fund, LP and Casdin Partners FO1-MSV LP, and Casdin Partners GP, LLC is the general partner of Casdin Partners Master Fund LP and Casdin Partners FO1-MSV LP. Eli Casdin is the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. As such, each of the foregoing may be deemed to have or share beneficial ownership of the Common Stock held directly by Casdin Partners Master Fund, LP.
    (6)
    The shares reflected as beneficially owned by Mr. Meister include 104,541,935 shares of Common Stock owned by investment funds advised by Corvex Management, L.P., which may be deemed to be indirectly beneficially owned by Keith Meister by virtue of Mr. Meister’s control of the general partner of Corvex Management, L.P. and the amount held by CMLS Holdings LLC.
    (7)
    Includes 22,286 shares issuable upon exercise of fully vested options and 12,836 shares of Common Stock that were issued upon vesting of restricted stock units, in each case that were granted to Mr. Casdin in connection with his service on the board of directors of the Issuer.
     

     
    SCHEDULE 13D
     
    This Amendment No. 4 (the “Amendment”) supplements the information set forth in the Schedule 13D (the “Schedule 13D”) filed with the United States Securities and Exchange Commission (the “SEC”) on August 2, 2021, as amended as of January 19, 2022, May 3, 2022 and December 5, 2022, by CMLS Holdings LLC, Keith Meister, Eli Casdin and the other Reporting Persons named therein, relating to the shares of common stock, par value $0.0001 per share (“Common Stock”), of GeneDx Holdings Corp. (f/k/a Sema4 Holdings Corp.) (the “Issuer”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Schedule 13D.
     
    The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. Items 3, 4 and 6 to the Schedule 13D are supplementally amended as follows, and Items 1 and 5 to the Schedule 13D is amended and restated as follows. Information with respect to each Reporting Person is given solely by such Reporting Person and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person, except as otherwise provided in Rule 13d-1(k).

    Item 1
    Security and Issuer.
    Class A common stock, par value $0.0001 per share (“Common Stock”), of GeneDx Holdings Corp. (the “Issuer”).
     
     
    Address of Issuer’s Principal Executive Offices.
     
    33 Ludlow Street
    North Tower, 8th floor
    Stamford, CT 06902
     
    Item 2(a)
    Name of Person Filing.
    This statement is filed on behalf of each of the following person (collectively, the “Reporting Persons”):
    i.      CMLS Holdings LLC (“CMLS Holdings”), the holder of record of the Common Stock (as defined below) reported herein;
    ii.     C-LSH LLC (“C-LSH”), member of CMLS Holdings;
    iii.    M-LSH LLC (“M-LSH”), member of CMLS Holdings;
    iv.    Eli Casdin (“Mr. Casdin”), a member of the Board of Managers of CMLS Holdings and the holder of record of the Common Stock reported
           herein;
    v.    Casdin Capital, LLC;
     vi.    Casdin Partners GP, LLC;
    v.     Casdin Partners Master Fund, L.P.;
     viii. Casdin FO1-MSV, LP;
     ix.   Keith A. Meister (“Mr. Meister”), member of the Board of Managers of CMLS Holdings and the managing member of M-LSH LLC; and
     x.     Corvex Management LP (“Corvex”)
     
    Any disclosures herein with respect to a Reporting Person is made by such Reporting Person.
     
    The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
     
    The Reporting Persons have entered into a joint filing agreement, filed as Exhibit A to this Schedule 13D, pursuant to which the Reporting Persons agreed to file the Schedule 13D and any amendments thereto in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

    Item 2(b)
    Address of Principal Business Office
    The address of the principal business office of each of the Reporting Persons other than CMLS Holdings, M-LSH, Mr. Meister and Corvex is c/o Casdin Capital, LLC, 1350 Avenue of the Americas, Suite 2600, New York, NY 10019.
     
    The address of the principal business office of each of CMLS Holdings, M-LSH, Mr. Meister and Corvex is c/o Corvex Management LP, 667 Madison Avenue, New York, NY 10065.
     
    Item 2(c)
    The principal occupation of Mr. Casdin is serving as Chief Investment Officer of Casdin Capital, LLC, the principal business of which is serving as investment adviser to its clients.  The principal business of Casdin Partners Master Fund, L.P. and Casdin FO1-MSV, LP is purchasing, holding and selling securities for investment purposes.
     
    The principal occupation of Mr. Meister is serving as Managing Partner of Corvex Management LP, the principal business of which is serving as an investment adviser of private investment funds, whose principal business is investing in securities.



    Item 2(d)
    None of the Reporting Persons have been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
     
    Item 2(e)
    None of the Reporting Persons has been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction resulting in any judgment, decree or final order enjoining them from engaging in future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.
     
    Item 2(f)
    Citizenship
    i.               CMLS Holdings is a Delaware limited liability company;
    ii. C-LSH is a Delaware limited liability company;
    iii.             M-LSH is a Delaware limited liability company;
    iv.             Mr. Casdin is a citizen of the United States of America;
    v.              Casdin Capital, LLC is a Delaware limited liability company;
     vi.             Casdin Partners GP, LLC is a Delaware limited liability company;
    v.             Casdin Partners Master Fund, L.P. is a Delaware limited partnership;
    viii.             Casdin FO1-MSV, LP is a Delaware limited partnership;
     ix.             Mr. Meister is a citizen of the United States of America; and
     x.              Corvex is a Delaware limited partnership.
     

    Item 3 Source and Amount of Funds or Other Consideration.

    Item 4 is hereby incorporated by reference.
     
    Item 4 Source and Amount of Funds or Other Consideration
     
    On January 26, 2023, investment funds advised by Corvex Management LP, the general partner of which is controlled by Mr. Meister, agreed to acquire as part of a registered direct offering directly from the issuer 77,663,376 shares of Common Stock (the “Initial Direct Offering Shares”) for an aggregate purchase price of approximately $27,182,181, funded by cash on hand and agreed to acquire an additional 22,336,624 shares of Common Stock (the “Additional Direct Offering Shares” and, together with the Initial Direct Offering Shares, the “Corvex Shares”) after stockholder approval (or waiver of such approval requirement) for an additional aggregate purchase price of approximately $7,817,818.  The Corvex Shares were acquired pursuant to a subscription agreement subject to typical representations and warranties and a six-month lock up, closing contemporaneously with the underwritten offering described below.  The description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Subscription Agreement, which is incorporated by reference to Exhibit 1.

    On January 31, 2023, Casdin Partners Master Fund, LP acquired 71,428,542 shares of Common Stock (the “Casdin Master Fund Shares”) for approximately $24,999,990, and Casdin Partners FO1-MSV LP acquired 14,285,743 shares of Common Stock (the “Casdin FO1-MSV Shares” and collectively together with the Casdin Master Fund Shares, the “Casdin Shares”) for approximately $5,000,010.  The price included underwriter’s commission, funded by cash on hand as part of an underwritten public offering.

    Item 5 Interest in the Securities of the Issuer
     
    The information set forth in the facing pages of this Schedule 13D with respect to the shared beneficial ownership of Common Stock by the Reporting Persons is incorporated by reference into this Item 5.
     
    The information set forth in Items 2, 3 and 4 is hereby incorporated by reference into this Item 5.
     
    (a) The aggregate number of shares of Common Stock and the percentage of total outstanding shares of Common Stock beneficially owned by the Reporting Persons is set forth below.
     
    References to percentage ownerships of shares of Common Stock in this Statement are based on 810,000,334 shares of Common Stock outstanding as reported in the Issuer’s final prospectus on Form 424 filed with the SEC on January 30, 2023 following the offerings referenced above reduced by the 22,336,624 Additional Direct Offering Shares (as defined above) plus 185,000 shares that the Issuer has informed the Reporting Persons that were issued as a partial exercise of the overallotment option.  The filing of this Statement shall not be construed as an admission that a Reporting Person beneficially owns the shares held by any other Reporting Person.
     
    (b) Eli Casdin has the sole power to vote or direct the vote of 35,122 shares of Common Stock (including 22,286 vested options) and shared power to vote or to direct the vote and shared power to dispose or to direct the disposition of 119,882,204 shares of Common Stock.

    Keith Meister has the sole power to vote or to direct the vote and sole power to dispose or to direct the disposition of 86,811,516 shares of Common Stock and shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 17,730,419 shares of Common Stock.



    The beneficial ownership of the shares of Common Stock reported herein does not include shares underlying unvested options to purchase shares of Common Stock or unvested restricted stock units held by Mr. Meister or Mr. Casdin as previously described in Item 6 of Schedule 13D or the Subsequent Corvex Shares.

    Each of CMLS, C-LSH and M-LSH shared power to vote or to direct the vote and shared power to dispose or to direct the disposition of the 17,730,419 shares of Common Stock reported in (a) above. The shared beneficial ownership of each of Messrs. Casdin,  Meister, CMLS, C-LSH and M-LSH includes warrants to acquire 6,736,669 shares of Common Stock.

    Each of Casdin Capital, LLC and Casdin Partners GP, LLC has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 102,151,785 shares of Common Stock.

    Casdin Partners Master Fund, L.P has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 87,866,402 shares of Common Stock.

    Casdin Partners FO1-MSV, LP has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 14,285,743 shares of Common Stock.

    Corvex has sole power to vote or direct the vote and sole power to dispose or to direct the disposition of 86,811,516 shares of Common Stock.

    (c) Except with respect to the 77,663,376 Initial Direct Offering Shares to be acquired upon the closing of the offering and the 85,714,285 Casdin Shares described in Item 4 above, the Reporting Persons have not effected any transactions in the Issuer’s Common Stock during the past 60 days and not previously reported in the Schedule 13D.
     
    (d) Other than the Reporting Persons, the funds that Corvex manages and the investors in the funds managed by Corvex and Casdin Capital LLC, no person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock beneficially owned by the Reporting Persons.
     
    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
     
    The information set forth in Item 4 above is hereby incorporated by reference into this Item 6.
    Item 7. Material to be Filed as Exhibits
    Exhibit A – Joint Filing Agreement
    Exhibit 1 – Form of Subscription Agreement, dated January 26, 2023, with the Issuer (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 30, 2023).

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 1, 2023
    CMLS HOLDINGS LLC
     
     
     
    By:
    /s/ Keith A. Meister
     
    Name:
    Keith A. Meister
     
    Title:
    Manager
     
     
    Date: February 1, 2023
    C-LSH LLC
     
     
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
     
     
    Date: February 1, 2023
    M-LSH LLC
     
     
     
    By:
    /s/ Keith A. Meister
     
    Name:
    Keith A. Meister
     
    Title:
    Managing Member
     
     
    Date: February 1, 2023
    /s/ Eli Casdin
     
    Eli Casdin
       
    Date: February 1, 2023
    CASDIN CAPITAL, LLC
     
     
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
       
    Date: February 1, 2023
    CASDIN PARTNERS GP, LLC
     
     
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
       
       
    Date: February 1, 2023
    CASDIN PARTNERS MASTER FUND, L.P.
     
     
     
    By:  Casdin Capital LLC, its Investment Adviser
         
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
       
    Date: February 1, 2023
    CASDIN PARTNERS FO1-MSV, LP
     
     
     
    By:  Casdin Capital LLC, its Investment Adviser
         
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
     
     
    Date: February 1, 2023
    /s/ Keith A. Meister
     
    Keith A. Meister
       
    Date: February 1, 2023
    CORVEX MANAGEMENT LP
     
     
     
    By:
    /s/ Keith A. Meister
     
    Name:
    Keith A. Meister
     
    Title:
    Managing Partner
       


    EXHIBIT A
    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    Date: February 1, 2023
    CMLS HOLDINGS LLC
     
     
     
    By:
    /s/ Keith A. Meister
     
    Name:
    Keith A. Meister
     
    Title:
    Manager
     
     
    Date: February 1, 2023
    C-LSH LLC
     
     
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
     
     
    Date: February 1, 2023
    M-LSH LLC
     
     
     
    By:
    /s/ Keith A. Meister
     
    Name:
    Keith A. Meister
     
    Title:
    Managing Member
     
     
    Date: February 1, 2023
    /s/ Eli Casdin
     
    Eli Casdin
       
    Date: February 1, 2023
    CASDIN CAPITAL, LLC
     
     
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
       
    Date: February 1, 2023
    CASDIN PARTNERS GP, LLC
     
     
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
       
       
    Date: February 1, 2023
    CASDIN PARTNERS MASTER FUND, L.P.
     
     
     
    By:  Casdin Capital LLC, its Investment Adviser
         
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
       
    Date: February 1, 2023
    CASDIN PARTNERS FO1-MSV, LP
     
     
     
    By:  Casdin Capital LLC, its Investment Adviser
         
     
    By:
    /s/ Eli Casdin
     
    Name:
    Eli Casdin
     
    Title:
    Managing Member
     
     
    Date: February 1, 2023
    /s/ Keith A. Meister
     
    Keith A. Meister




       
    Date: February 1, 2023
    CORVEX MANAGEMENT LP
     
     
     
    By:
    /s/ Keith A. Meister
     
    Name:
    Keith A. Meister
     
    Title:
    Managing Partner
       


    Get the next $SMFR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMFR

    DatePrice TargetRatingAnalyst
    12/7/2022$3.00 → $1.00Buy → Neutral
    Goldman
    8/16/2022$4.00 → $2.00Buy → Hold
    Jefferies
    6/2/2022$3.50Buy
    Goldman
    11/19/2021$12.00Buy
    Goldman Sachs
    10/8/2021$12.00Buy
    BTIG Research
    9/30/2021$13.00Outperform
    Cowen & Co.
    9/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $SMFR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

      STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial

      8/26/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Announces Chief Financial Officer Transition Plan

      Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo

      6/14/22 4:30:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    SEC Filings

    See more
    • Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      1/8/24 8:58:39 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by Sema4 Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      11/15/23 5:17:42 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by Sema4 Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      11/3/23 4:06:35 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Saad Kareem sold $625 worth of shares (193 units at $3.24) and converted options into 546 shares, increasing direct ownership by 1% to 24,467 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/23/24 4:10:20 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Ryan Jason gifted 73,614 shares, closing all direct ownership in the company (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/12/24 4:31:01 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Saad Kareem sold $271 worth of shares (105 units at $2.58), decreasing direct ownership by 0.43% to 24,114 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/4/24 5:03:07 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sema4 Holdings Corp downgraded by Goldman with a new price target

      Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      12/7/22 8:08:36 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Holdings Corp downgraded by Jefferies with a new price target

      Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously

      8/16/22 7:58:53 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Goldman resumed coverage on Sema4 Holdings Corp with a new price target

      Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50

      6/2/22 7:21:25 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

      STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming

      12/30/22 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

      STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai

      12/5/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Sema4 Holdings Corp.

      SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)

      2/9/24 7:10:06 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/17/23 4:15:23 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13G/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

      6/9/23 4:15:22 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Financials

    Live finance-specific insights

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

      Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

      11/14/22 8:02:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

      STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

      11/4/22 4:05:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ryan Jason bought $161,368 worth of shares (114,742 units at $1.41) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/20/23 4:32:17 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Pfenniger Richard C Jr bought $14,889 worth of shares (10,000 units at $1.49), increasing direct ownership by 92% to 20,918 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/8/23 7:19:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology